STERIS PLC (NYSE:STE) Passes the 'Caviar Cruise' Quality Investing Screen

By – Last update:

Quotes Stocks Mentioned

Article Mentions:

For investors aiming to assemble a portfolio of durable, high-standard businesses, the ideas of quality investing present a strong framework. This method centers on finding companies with lasting competitive strengths, sound financial condition, and the capacity to produce better returns on capital over many years. One organized way to find these companies is the "Caviar Cruise" stock screen, which uses a set of strict numerical filters to find firms with a record of profitable expansion, good cash production, and effective use of capital. The screen highlights measures like steady sales and earnings expansion, high returns on invested capital, reasonable debt, and trustworthy earnings, all signs of a business made to last.

STERIS PLC (NYSE:STE)

A recent result from this screening process is STERIS PLC (NYSE:STE), a worldwide supplier of infection prevention and procedural products and services for healthcare, pharmaceutical, and research clients. A look at its financial picture shows several important traits that match the quality investing view closely.

Matching the Main Standards for Quality

The Caviar Cruise screen is constructed on basic filters made to distinguish outstanding businesses from the simply adequate. STERIS shows strength across these main measures.

  • Profitable Expansion: The screen demands a minimum 5% compound annual growth rate (CAGR) for both sales and EBIT (earnings before interest and taxes) over five years. STERIS easily surpasses this, with a sales CAGR of 6.66% and a more notable EBIT CAGR of 12.57%. Importantly, EBIT expansion has been faster than sales growth, a sign of better operational effectiveness and possible pricing strength, exactly the type of profitable scaling quality investors look for.
  • Outstanding Capital Effectiveness: A main idea of quality investing is evaluating how effectively a company uses its capital. The screen requires a Return on Invested Capital (leaving out cash, goodwill, and intangibles) above 15%. STERIS reports a solid 25.19% on this measure, showing it produces considerable profit from the main capital used in its business. This high return points to a strong competitive position and skilled management.
  • Financial Strength and Cash Flow Trustworthiness: Quality companies are not weighed down by debt and turn accounting profits into actual cash. The screen searches for a Debt-to-Free Cash Flow ratio under 5, meaning all debt could be paid off with five years of cash flow. STERIS displays a very sound ratio of 2.07, showing a strong balance sheet. Also, its average Profit Quality over five years is a remarkable 186.77%, meaning its free cash flow production has greatly exceeded its net income. This shows earnings are not only trustworthy but also supply plenty of cash for new investment, dividends, or paying down debt.

A Broad Fundamental Picture

A look at STERIS's wider fundamental analysis report supports the image shown by the screen. The company receives a good overall score, with specific strong points in Profitability and Financial Health.

  • Its profitability measures, including Return on Assets, Return on Equity, and Operating Margin, place in the highest group of its Health Care Equipment & Supplies industry peers.
  • Financial health is supported by a strong Altman-Z score (showing low bankruptcy risk) and the positive debt ratios already noted.
  • The Growth score is average, recognizing a strong past performance while observing that analyst forecasts for future expansion are more conservative. The Valuation score is neutral, indicating the stock is not clearly low-priced or high-priced compared to its own history, the market, and its industry, a common result for a high-quality company.

Is STERIS a "Buy-and-Hold" Possibility?

The Caviar Cruise method, drawn from quality investing ideas, is naturally long-term. It looks for companies deserving of a "buy-and-hold-forever" perspective. STERIS's picture backs this view in a few ways. Its business, supplying necessary sterilization, surgical, and laboratory services, meets a constant, required need in healthcare and life sciences, areas with stable long-term demand. The mix of high returns on capital, good cash flow conversion, and a careful balance sheet supplies the financial strength to endure economic changes. While future expansion may slow from past levels, the company's established market position and reliable operation suggest it is constructed for long life.

For investors wanting to use this strict method to locate other possible quality investments, the Caviar Cruise screen is a useful beginning. You can review the present screen results and method in full here.


Disclaimer: This article is for information only and does not make up financial guidance, a suggestion, or an offer to buy or sell any security. Investing carries risk, including the possible loss of original investment. You should do your own complete research and talk with a qualified financial advisor before making any investment choices.